U.S. markets close in 33 minutes

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.8300+0.1400 (+3.79%)
As of 03:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.6900
Bid3.7900 x 800
Ask3.8200 x 1200
Day's Range3.5100 - 3.8400
52 Week Range1.7400 - 7.7500
Avg. Volume956,841
Market Cap240.634M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-3.0400
Earnings DateMay 08, 2023 - May 12, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OMER

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Omeros Corporation
    CYTK: Lowering target price to $36.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Insider Monkey

    Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript

    Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good afternoon. And welcome to today’s earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode. After the company’s remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company’s […]

  • Thomson Reuters StreetEvents

    Q4 2022 Omeros Corp Earnings Call

    Q4 2022 Omeros Corp Earnings Call

  • Business Wire

    Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

    SEATTLE, March 13, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, wh